The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells

Jourdan, Michel; Ferlin, Martine; Legouffe, Eric; Horváthová, Mira; Liautard, Jean‐Pierre; Rossi, Jean François; Wijdenes, John; Brochier, J; Klein, Bernard

doi:10.1046/j.1365-2141.1998.00623.x

Cited by 126 publications

(91 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After 6 days, cell viability was measured by CD138-FITC (IQ products, Groningen, The Netherlands; clone B-A38)/PI (Pharmingen) staining and referred to the medium control (Jourdan et al, 1998). PI of 1 ml at the concentration of 50 mg/ ml was used.…”

Section: Survival Of Primary Mmcsmentioning

confidence: 99%

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

et al. 2009

View full text Add to dashboard Cite

Pathogenesis of multiple myeloma is associated with an aberrant expression of pro-proliferative, pro-angiogenic and bone-metabolism-modifying factors by malignant plasma cells. Given the frequently long time span from diagnosis of early-stage plasma cell dyscrasias to overt myeloma and the mostly low proliferation rate of malignant plasma cells, we hypothesize these to similarly express a novel class of inhibitory factors of potential prognostic relevance. Bone morphogenic proteins (BMPs) represent possible candidates as they inhibit proliferation, stimulate bone formation and have an effect on the survival of cancer patients. We assessed the expression of BMPs and their receptors by Affymetrix DNA microarrays (n ¼ 779) including CD138-purified primary myeloma cell samples (n ¼ 635) of previously untreated patients. BMP6 is the only BMP expressed by malignant and normal plasma cells. Its expression is significantly lower in proliferating myeloma cells, myeloma cell lines or plasmablasts. BMP6 significantly inhibits the proliferation of myeloma cell lines, survival of primary myeloma cells and in vitro angiogenesis. A high BMP6 expression in primary myeloma cell samples delineates significantly superior overall survival for patients undergoing high-dose chemotherapy independent of conventional prognostic factors (International Staging System (ISS) stage, b 2 microglobulin).

show abstract

Section: Survival Of Primary Mmcsmentioning

confidence: 99%

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

et al. 2009

View full text Add to dashboard Cite

show abstract

“…We have shown that the MI15 mAb recognizes syndecan-1 and that syndecan-1 is only present in tumoral samples on viable myeloma cells. 27,28 In addition, this antigen is cleaved by chymopapain without affecting cell viability using a procedure previously described for CD34 purification which allows a large scale purification of myeloma cells. 29 To purify myeloma cells, mononuclear cells from tumoral samples were suspended in Hank's buffer containing 1% of human serum albumin (Hank's/HSA) and 0.5% human Ig at a concentration of 2 × 10 7 cells/ml and incubated for 30 min at 4°C.…”

Section: Purification Of Freshly Explanted Primary Myeloma Cellsmentioning

confidence: 99%

Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors

Vos

Rebouissou³

et al. 2000

Leukemia

View full text Add to dashboard Cite

We have previously reported obtaining two monoclonal antibodies (mAb) against the human gp130 interleukin-6 (IL-6) transducer which made possible the dimerization of gp130 and the activation of several IL-6-driven functions when used together. We report here that these mAb induce gp130-mediated signaling in human myeloma cells and support the survival and the long-term growth of five IL-6-dependent human myeloma cell lines. Their agonist activity is not affected by neutralizing antibodies to IL-6 or IL-6R. These mAb induce a transient proliferation of primary myeloma cells from most patients with multiple myeloma. Again, IL-6 inhibitors do not affect this agonist activity. By using highly purified primary myeloma cells, we found that these anti-gp130 mAb supported the long-term survival of primary myeloma cells from five patients with primary plasma cell leukemia but failed to induce their long-term growth. For patients with fulminant disease and secondary extramedullary proliferation, the antibodies supported a long-term survival and growth, and anti-gp130 mAbdependent cell lines were obtained. For patients with medullary involvement only, a co-stimulatory signal is necessary, together with gp130 activation, to trigger cell survival and cycling. Leukemia (2000) 14, 188-197.

show abstract

“…CD138, also known as syndecan-1, is a sulphate-rich proteoglycan adhesion molecule usually expressed during B-cells differentiation into plasma cells (Jourdan et al, 1998). Two studies proposed the positive expression of CD138 as a marker of poor prognosis in DLBCL patients (Hoffmann et al, 2005;Oh and Park, 2006).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Bodoor

Matalka²,

Hayajneh³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The diffuse large B-cell lymphoma (DLBCL) encompasses two major groups of tumors with uneven survival outcomes -germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB). In the present study, we investigated the expression of GCB markers (BCL-6 and CD10) and non-GCB markers (CD138 and MUM-1) in an effort to evaluate their prognostic value. Paraffin-embedded tumor biopsies of 46 Jordanian DLBCL patients were analyzed, retrospectively, by immunohistochemistry to investigate the expression of BCL-6, CD10, CD138 and MUM-1. In addition, survival curves were calculated with reference to marker expression, age, sex and nodal involvement. Positive expression of BCL-6, CD10, CD138 and MUM-1 was shown in 78%, 61%, 39% and 91% of the cases, respectively, that of BCL-6 being associated with better overall survival (p = 0.02), whereas positive CD138 was linked with poor overall survival (p = 0.01). The expression of CD10 and MUM-1 had no impact on the overall survival. Among the clinical characteristics studied, diagnosis at an early age, nodal involvement and maleness were associated with a higher overall survival for DLBCL patients. Our results underline the importance of BCL-6 as a marker of better prognosis and CD138 as a marker of poor prognosis for DLBCL patients.

show abstract

The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells

Cited by 126 publications

References 25 publications

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Contact Info

Product

Resources

About